Good morning :)
Stocks Collections

Top CDMO Stocks in India: List and Guide (2026)

India's pharmaceutical outsourcing industry has grown steadily as global drug companies look to reduce costs and diversify supply chains. CDMO stocks in India represent listed companies that earn by developing and manufacturing pharmaceutical products on behalf of global innovators and generic drug companies. Here, we will be covering CDMO stocks and factors to consider when analysing them.

Best CDMO Stocks in India (2026)

CDMO Stocks in India

Here's the list of Top CDMO Stocks in India

Created by

@82600328260032

Showing 1 - 20 of 252 results

last updated at 9:45 PM IST 
NameStocks (252)↓↓Sub-SectorSub-Sector↓↓Market CapMarket Cap↓↓Close PriceClose Price↓↓PE RatioPE Ratio↓↓1M Return1M Return↓↓1D Return1D Return↓↓Return on EquityReturn on Equity↓↓PB RatioPB Ratio↓
1.Sun Pharmaceutical Industries LtdSUNPHARMAPharmaceuticalsPharmaceuticals4,37,830.654,37,830.651,824.801,824.8038.1438.14-2.84-2.840.240.2415.6615.666.046.04
2.Divi's Laboratories LtdDIVISLABLabs & Life Sciences ServicesLabs & Life Sciences Services1,79,642.591,79,642.596,767.006,767.0069.9569.950.240.241.551.5515.3515.3512.0012.00
3.Torrent Pharmaceuticals LtdTORNTPHARMPharmaceuticalsPharmaceuticals1,50,455.921,50,455.924,445.504,445.5069.5569.552.032.030.060.0617.1917.198.568.56
4.Cipla LtdCIPLAPharmaceuticalsPharmaceuticals1,09,503.431,09,503.431,355.501,355.5028.2328.23-4.68-4.680.350.3511.7911.793.173.17
5.Zydus Lifesciences LtdZYDUSLIFEPharmaceuticalsPharmaceuticals1,08,109.781,08,109.781,074.401,074.4021.4521.456.386.381.221.2218.6818.684.104.10
6.Lupin LtdLUPINPharmaceuticalsPharmaceuticals1,06,402.581,06,402.582,327.102,327.1019.9519.953.893.892.432.4320.7320.736.156.15
7.Dr Reddy's Laboratories LtdDRREDDYPharmaceuticalsPharmaceuticals1,05,545.171,05,545.171,267.501,267.5025.1525.15-5.16-5.16-0.12-0.1218.1918.193.113.11
8.Mankind Pharma LtdMANKINDPharmaceuticalsPharmaceuticals99,366.8399,366.832,406.002,406.0051.9451.94-4.03-4.031.771.7716.4916.496.826.82
9.Aurobindo Pharma LtdAUROPHARMAPharmaceuticalsPharmaceuticals83,067.3183,067.311,443.701,443.7023.7023.70-4.66-4.661.501.5011.1511.152.542.54
10.Laurus Labs LtdLAURUSLABSPharmaceuticalsPharmaceuticals73,949.3673,949.361,368.801,368.8083.2083.203.413.41-0.07-0.0717.7217.7213.6213.62
11.Biocon LtdBIOCONBiotechnologyBiotechnology67,023.3167,023.31413.85413.85173.82173.82-3.41-3.410.490.493.823.822.422.42
12.Alkem Laboratories LtdALKEMPharmaceuticalsPharmaceuticals64,230.3264,230.325,372.005,372.0027.9027.90-1.70-1.700.460.4618.7118.715.175.17
13.Glenmark Pharmaceuticals LtdGLENMARKPharmaceuticalsPharmaceuticals60,786.0560,786.052,154.002,154.0044.6444.64-7.54-7.540.810.8112.5412.546.876.87
14.Abbott India LtdABBOTINDIAPharmaceuticalsPharmaceuticals55,556.3055,556.3026,145.0026,145.0035.8035.80-6.77-6.770.730.7335.6635.6613.1213.12
15.Anthem Biosciences LtdANTHEMBiotechnologyBiotechnology44,948.6044,948.60798.10798.1075.9575.953.053.053.993.9920.8220.8218.6518.65
16.IPCA Laboratories LtdIPCALABPharmaceuticalsPharmaceuticals39,161.7839,161.781,543.601,543.6034.3234.32-3.53-3.530.320.329.169.164.674.67
17.Ajanta Pharma LtdAJANTPHARMPharmaceuticalsPharmaceuticals38,400.2138,400.213,073.603,073.6036.3636.36-3.07-3.07-0.19-0.1925.0225.0210.1310.13
18.GlaxoSmithKline Pharmaceuticals LtdGLAXOPharmaceuticalsPharmaceuticals38,390.8038,390.802,266.202,266.2037.0637.06-6.59-6.593.023.0249.1149.1116.9316.93
19.Gland Pharma LtdGLANDPharmaceuticalsPharmaceuticals36,327.4236,327.422,202.202,202.2035.3635.366.986.980.210.217.827.823.973.97
20.J B Chemicals and Pharmaceuticals LtdJBCHEPHARMPharmaceuticalsPharmaceuticals35,298.8335,298.832,198.502,198.5049.7549.754.084.080.130.1318.6918.698.498.49
Edit Filters

Analyse CDMO Stocks further

Visit 'CDMO Stocks' ScreenerScreener

Disclaimer: Please note that the above table is for informational purposes only, and is not recommendatory. Please do your own research or consult your financial advisor before investing. The data is derived from Tickertape Stock Screener and is subject to real-time updates.

Selection criteria: Category: 'Pharmaceuticals'. Stocks are sorted by market capitalisation, highest to lowest.

What is CDMO?

A CDMO, or Contract Development and Manufacturing Organisation, is a company that provides drug development and manufacturing services to pharmaceutical, biotechnology, and medical device companies. CDMOs handle the entire process on behalf of their clients, from early-stage drug development and clinical manufacturing through to commercial-scale production and packaging.

What are CDMO Stocks?

CDMO stocks are shares of listed companies that earn a significant portion of their revenue from contract development and manufacturing services for global pharmaceutical clients. These companies do not sell medicines under their own brand to end consumers. Instead, they manufacture APIs, formulations, biologics, or specialised drug products on behalf of innovator pharma companies and generic drug makers.

Overview of CDMO Stocks in India

Sun Pharmaceutical Industries Ltd

Sun Pharmaceutical Industries Ltd is India’s largest pharmaceutical company by market presence. It manufactures branded generics, speciality medicines, APIs, and formulations for both the Indian and global markets. Its performance depends on product launches, regulatory approvals, US business trends, demand for speciality drugs, and pricing pressure.

Divi's Laboratories Ltd

Divi’s Laboratories Ltd is an Indian pharmaceutical company focused on active pharmaceutical ingredients, intermediates, nutraceutical ingredients, and custom synthesis. It serves domestic and global pharma clients.

Torrent Pharmaceuticals Ltd

Torrent Pharmaceuticals Ltd is a major Indian pharma company with a strong presence in branded generics. It focuses on therapies such as cardiovascular, central nervous system, gastrointestinal, diabetes, and women’s healthcare. Its performance depends on domestic growth, new launches, margins, exports, and regulatory approvals.

Cipla Ltd

Cipla Ltd is a leading pharmaceutical company known for respiratory, anti-retroviral, urology, cardiac, and chronic therapy products. It operates across India, the US, South Africa, and other global markets. Its performance depends on respiratory portfolio growth, product approvals, exports, pricing trends, and regulatory compliance.

Zydus Lifesciences Ltd

Zydus Lifesciences Ltd is an Indian pharma company involved in formulations, vaccines, biosimilars, APIs, and consumer wellness products. It serves both domestic and international markets. Its performance depends on product pipeline, US approvals, domestic branded business, research output, and manufacturing compliance.

How to Invest in CDMO Stocks?

Here's how you can invest in CDMO stocks using Tickertape -

  1. Create an account on the Tickertape or log in if you already have one.
  2. Open CDMO Stocks Screener
  3. Filter stocks based on 200+ parameters. Tickertape provides comprehensive data on each stock, including financials, performance metrics, future projections, red flags, and more. You can review this data to assess each company's financial health and potential in-depth.
  4. Once you've decided on a stock, you can place a buy order through your brokerage account linked to Tickertape.

You can stay updated with each of your favourite stocks' alerts and announcements with Tickertape Alerts. Further, you can analyse your overall portfolio and potential red flags in it by connecting it to Tickertape. Check out the detailed analysis of your portfolio now!

Advantages of Investing in CDMO Stocks

Large Pharma Manufacturing Base

India has a strong base in pharmaceuticals, generics, vaccines, APIs, and formulations. IBEF notes that India supplies one in five generic medicines globally and has moved to third place in global pharmaceutical export volume. This gives Indian CDMO companies a large manufacturing ecosystem to build on.

Export-Led Opportunity

India’s pharma exports stood at $30.5 bn in FY25, with exports reaching 191 countries. About 50% of exports went to highly regulated markets such as the US and Europe. This matters for CDMO sector stocks because regulated-market capability can improve credibility with global pharma clients.

Growth in Outsourcing Demand

India’s CRDMO industry is expected to grow from $7 bn to $ 14bn by 2028, according to a Macquarie Equity Research estimate cited by IBEF. This reflects rising pharma outsourcing, regulatory support, and global supply chain shifts.

China+1 Supply Chain Shift

Global pharma companies are reviewing supply chains and looking beyond single-country dependence. IBEF, citing McKinsey, notes that India may capture 8-10% of global work outsourced to CRDMOs by 2033. This can support Indian CDMO companies with development, manufacturing, and research capabilities.

Policy Support For Advanced Manufacturing

The government’s PLI scheme for pharmaceuticals aims to improve India’s manufacturing capability and promote high-value products such as biopharmaceuticals, complex generics, patented drugs, anti-cancer drugs, and auto-immune drugs. This can support CDMO companies working in specialised and higher-value manufacturing areas.

Risks of Investing in CDMO Stocks

Client Concentration Risk

Many CDMO companies depend on a small number of large global pharmaceutical clients for a significant portion of revenue. If a key client does not renew a contract, shifts manufacturing in-house, or faces its own business challenges, it can directly impact the CDMO's revenue and earnings.

Regulatory Compliance Risk

CDMO facilities require continuous compliance with stringent global regulatory standards. A warning letter, import alert, or observations from the USFDA or EMA can disrupt manufacturing operations and delay or cancel contract deliveries. Regulatory setbacks can have an outsized impact on revenue in a contract-dependent business.

Project Failure and Pipeline Risk

Clinical-stage CDMO projects carry the risk that a client's drug may fail in trials. When a molecule in development fails, the associated manufacturing contract is discontinued. CDMOs with a higher proportion of development-stage projects relative to commercial-stage ones face more revenue variability from pipeline attrition.

Pricing Pressure from Chinese Competition

Chinese CDMO and API manufacturers have historically competed on price, and periods of aggressive pricing from Chinese suppliers can put pressure on Indian firms. While geopolitical factors have reduced this risk to some extent, Indian CDMOs that compete on cost rather than complexity remain exposed to this dynamic.

High Capital Expenditure Requirements

Building and maintaining CDMO capabilities, particularly for complex molecules, biologics, and high-potency drugs, requires significant ongoing capital investment. Companies that expand aggressively may face pressure on return ratios and free cash flow during the ramp-up period before new capacity generates sufficient revenue.

Inventory Destocking Cycles

Global pharmaceutical companies periodically manage inventory by drawing down existing stock before placing new manufacturing orders. These destocking phases can cause short-term revenue gaps for CDMOs, even when the underlying client relationship remains intact.

Install the Tickertape app and enjoy a more hands-on investing experience
  • portfolio-iconReceive real-time market alerts for timely decisions
  • portfolio-iconMonitor your portfolio from the palm of your hands
  • portfolio-iconWatchlist stocks and mutual funds to stay updated
Download Now

Factors to Consider Before Investing in CDMO Stocks

Revenue Mix

A higher share of commercial-stage CDMO revenue provides better near-term visibility compared to development-stage projects. Reviewing the split between commercial molecules and clinical-stage work can help to understand the reliability of revenue streams and how much of the pipeline is at risk of project failure.

Client Base Diversification

CDMO companies with a broad and diversified client base are less exposed to revenue concentration risk. Reviewing the number of active projects, the spread across small, mid-sized, and large global pharma clients, and any dependence on a single molecule or product can give a clearer picture of business resilience.

Regulatory Compliance History

A consistent record of clean regulatory inspections from the USFDA, EMA, and other agencies is essential for CDMO companies in India. Investors can check the company's recent inspection outcomes and whether any facilities have had warning letters or remediation requirements, as these affect both operations and client confidence.

Capability Depth and Complexity

CDMOs that have invested in complex chemistries, biologics, high-potency APIs, peptides, or specialised formulations can target higher-margin projects and face less competition from lower-cost manufacturers. Reviewing the type of molecules a company handles and whether it is moving up the value chain is relevant to understanding its medium-term growth potential.

Capital Expenditure and Return Ratios

CDMO companies go through periods of heavy capex when building new facilities or expanding capabilities. Investors may track capital expenditure plans against current capacity utilisation and review return on equity and return on capital employed over time to assess whether past investments have generated appropriate returns.

Conclusion

CDMO sector stocks give investors exposure to India's growing pharmaceutical outsourcing industry. As global drug companies shift manufacturing away from China and increase outsourcing of complex molecules, Indian CDMOs are well-placed to capture a rising share of this demand. However, client concentration, regulatory compliance, and pipeline risks mean that CDMO stocks require careful analysis of business fundamentals alongside the sector's structural tailwinds.



Investors looking to study CDMO stocks can use the Tickertape Stock Screener to filter stocks across 200+ financial and operational parameters, and identify companies in the CDMO space that align with their investment approach.

Popular Stock Collections

Popular Mutual Fund Collections

Frequently Asked Questions About CDMO Stocks

  1. What is CDMO?

    A CDMO, or Contract Development and Manufacturing Organisation, is a company that provides drug development and manufacturing services to pharmaceutical and biotechnology companies. CDMOs handle the process from early-stage development through to commercial manufacturing on behalf of their clients, allowing pharma companies to outsource production without building their own facilities.

  2. What are CDMO stocks?

    CDMO sector stocks are shares of listed companies that earn revenue primarily from contract development and manufacturing services for global pharmaceutical clients. Unlike branded pharma companies, CDMOs do not sell medicines under their own name. Their revenue depends on contract wins, order volumes, and the progression of client drug pipelines from development to commercial scale.

  3. Which are the top CDMO companies in India?

    As of 2nd June 2026, some of the top CDMO companies in India, sorted based on market cap, include:
    1. Sun Pharmaceutical Industries Ltd
    2. Divi's Laboratories Ltd
    3. Torrent Pharmaceuticals Ltd
    4. Cipla Ltd
    5. Zydus Lifesciences Ltd


    Disclaimer: The above information is for educational purposes only and should not be considered investment advice.

  4. What is the CDMO sector's growth outlook for India?

    India's CDMO market is projected to grow from $8.4 bn in 2024 to $15.4 bn by 2029, representing a compound annual growth rate of approximately 13.4%. This growth outpaces the global CDMO industry average, driven by the China-Plus-One diversification trend, rising global drug demand, and India's expanding capabilities in complex molecules, biologics, and speciality formulations.

  5. What are the advantages of investing in CDMO stocks in India?

    CDMO stocks in India offer exposure to pharma outsourcing, export-led manufacturing, and specialised drug production. India’s strong pharma base, cost-efficient manufacturing, skilled scientific talent, and global regulatory experience can support companies that serve domestic and international pharmaceutical clients.

    Disclaimer: The above information is for educational purposes only and should not be considered investment advice.

  6. What are the risks of investing in CDMO stocks in India?

    CDMO stocks can face risks from regulatory inspections, client concentration, pricing pressure, currency movement, delayed approvals, and capacity underutilisation. A warning letter, import alert, or loss of a major client can affect revenue, margins, and stock performance.

  7. Are CDMO stocks suitable for beginners?

    CDMO stocks may be difficult for beginners to analyse because they involve regulated markets, product approvals, client contracts, manufacturing quality, and global demand cycles. Beginners may need to review business segments, margins, regulatory history, cash flows, debt, and valuation before forming a view.

    Disclaimer: The above information is for educational purposes only and should not be considered investment advice.

  8. Are CDMO stocks a good investment?

    CDMO stocks are not automatically good investments. Their performance depends on client relationships, regulatory compliance, capacity use, product mix, margins, and global pharma outsourcing demand. Investors may review financials, business model, order visibility, and valuation before making any assessment.

    Disclaimer: The above information is for educational purposes only and should not be considered investment advice.

Disclaimer: This article is for informational purposes only. The content of the article including securities/investment products mentioned if any, should not in any manner be construed as an investment advice, recommendation, offer, solicitation to buy/hold/sell any securities/investment products. The securities quoted if any, are for illustration only and are not recommendatory. Investment in securities market are subject to market risks. Read all the related documents carefully before investing. Please consult a SEBI-registered financial advisor before investing.